Skip Nav Destination
Issues
1 December 2011
-
Cover Image
Cover Image
This image demonstrates unique genomic aberrations in adjacent stroma and epithelium in a benign serous ovarian cystadenofibroma. Pseudocolored FISH probes for chromosomes 12 (orange and green) and 15 (blue) identified clusters of epithelial cells with balanced tetrasomy alongside fibroblast cells triploid for chromosome 12. Nuclei were counterstained with DAPI. For details, see the article by Hunter and colleagues on page 7273 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Human Cancer Biology
Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites
Mei Zhao; Daisuke Sano; Curtis R. Pickering; Samar A. Jasser; Ying C. Henderson; Gary L. Clayman; Erich M. Sturgis; Thomas J. Ow; Reuben Lotan; Thomas E. Carey; Peter G. Sacks; Jennifer R. Grandis; David Sidransky; Nils Erik Heldin; Jeffrey N. Myers
A Novel Aldehyde Dehydrogenase-3 Activator Leads to Adult Salivary Stem Cell Enrichment In Vivo
Alice Banh; Nan Xiao; Hongbin Cao; Che-Hong Chen; Peiwen Kuo; Trevor Krakow; Brindha Bavan; Brian Khong; Mike Yao; Chi Ha; Michael J. Kaplan; Davud Sirjani; Kristin Jensen; Christina S. Kong; Daria Mochly-Rosen; Albert C. Koong; Quynh-Thu Le
Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification?
Sally M. Hunter; Michael S. Anglesio; Raghwa Sharma; C. Blake Gilks; Nataliya Melnyk; Yoke-Eng Chiew; Anna deFazio; for the Australian Ovarian Cancer Study Group; Teri A. Longacre; David G. Huntsman; Kylie L. Gorringe; Ian G. Campbell
Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition
Kai Zhu; Zhi Dai; Qi Pan; Zheng Wang; Guo-Huan Yang; Lei Yu; Zhen-Bin Ding; Guo-Ming Shi; Ai-Wu Ke; Xin-Rong Yang; Zhong-Hua Tao; Yi-Ming Zhao; Yi Qin; Hai-Ying Zeng; Zhao-You Tang; Jia Fan; Jian Zhou
Gene Expression Differences between Colon and Rectum Tumors
Rebeca Sanz-Pamplona; David Cordero; Antonio Berenguer; Flavio Lejbkowicz; Hedy Rennert; Ramon Salazar; Sebastiano Biondo; Xavier Sanjuan; Miguel A. Pujana; Laura Rozek; Thomas J. Giordano; Ofer Ben-Izhak; Hector I. Cohen; Philip Trougouboff; Jacob Bejhar; Yanina Sova; Gad Rennert; Stephen B. Gruber; Victor Moreno
Cancer Therapy: Preclinical
Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
Edmund C. Lee; Michael Fitzgerald; Bret Bannerman; Jill Donelan; Kristen Bano; Jennifer Terkelsen; Daniel P. Bradley; Ozlem Subakan; Matthew D. Silva; Ray Liu; Michael Pickard; Zhi Li; Olga Tayber; Ping Li; Paul Hales; Mary Carsillo; Vishala T. Neppalli; Allison J. Berger; Erik Kupperman; Mark Manfredi; Joseph B. Bolen; Brian Van Ness; Siegfried Janz
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
Kristy J. Gotink; Henk J. Broxterman; Mariette Labots; Richard R. de Haas; Henk Dekker; Richard J. Honeywell; Michelle A. Rudek; Laurens V. Beerepoot; René J. Musters; Gerrit Jansen; Arjan W. Griffioen; Yehuda G. Assaraf; Roberto Pili; Godefridus J. Peters; Henk M.W. Verheul
Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
Warren Fiskus; Srdan Verstovsek; Taghi Manshouri; Rekha Rao; Ramesh Balusu; Sreedhar Venkannagari; Nalabothula Narasimha Rao; Kyungsoo Ha; Jacqueline E. Smith; Stacey L. Hembruff; Sunil Abhyankar; Joseph McGuirk; Kapil N. Bhalla
Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
Steven I. Park; Jaideep Shenoi; Shani M. Frayo; Donald K. Hamlin; Yukang Lin; D. Scott Wilbur; Patrick S. Stayton; Nural Orgun; Mark Hylarides; Franz Buchegger; Aimee L. Kenoyer; Amanda Axtman; Ajay K. Gopal; Damian J. Green; John M. Pagel; Oliver W. Press
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Johannes M. Heuckmann; Michael Hölzel; Martin L. Sos; Stefanie Heynck; Hyatt Balke-Want; Mirjam Koker; Martin Peifer; Jonathan Weiss; Christine M. Lovly; Christian Grütter; Daniel Rauh; William Pao; Roman K. Thomas
Imaging, Diagnosis, Prognosis
CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1–Positive Acute Lymphoblastic Leukemia Patients
Ilaria Iacobucci; Anna Ferrari; Annalisa Lonetti; Cristina Papayannidis; Francesca Paoloni; Stefania Trino; Clelia Tiziana Storlazzi; Emanuela Ottaviani; Federica Cattina; Luciana Impera; Maria Chiara Abbenante; Marco Vignetti; Antonella Vitale; Leonardo Potenza; Stefania Paolini; Simona Soverini; Fabrizio Pane; Mario Luppi; Robin Foà; Michele Baccarani; Giovanni Martinelli
Cancer Therapy: Clinical
Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma
Geoffrey R. Weiss; William W. Grosh; Kimberly A. Chianese-Bullock; Yingdong Zhao; Hui Liu; Craig L. Slingluff, Jr; Francesco M. Marincola; Ena Wang
Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
John Fruehauf; Jose Lutzky; David McDermott; Charles K. Brown; Jean-Baptiste Meric; Brad Rosbrook; David R. Shalinsky; Katherine F. Liau; Andreas G. Niethammer; Sinil Kim; Olivier Rixe
Predictive Biomarkers and Personalized Medicine
Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
Aziz Zaanan; Jean-François Fléjou; Jean-François Emile; Guetz Gaëtan Des; Peggy Cuilliere-Dartigues; David Malka; Cédric Lecaille; Pierre Validire; Christophe Louvet; Philippe Rougier; Aimery de Gramont; Franck Bonnetain; Françoise Praz; Julien Taïeb
Reviewers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds